Letter to the Editor Regarding “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”

被引：0
|
作者：
Yafei Xie
Xiaowei Zhang
机构：
[1] Lanzhou University Second Hospital, Department of Cardiovascular Medicine
[2] Lanzhou University,Second Clinical Medical College
来源：
Cardiovascular Drugs and Therapy | 2022年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：571 / 572
页数：1
相关论文
共 50 条
  • [1] Letter to the Editor Regarding "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus"
    Xie, Yafei
    Zhang, Xiaowei
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (03) : 571 - 572
  • [2] Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
    Bertram Pitt
    Gabriel Steg
    Lawrence A. Leiter
    Deepak L. Bhatt
    Cardiovascular Drugs and Therapy, 2022, 36 : 573 - 573
  • [3] The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
    Pitt, Bertram
    Steg, Gabriel
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (03) : 561 - 567
  • [4] Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
    Bertram Pitt
    Gabriel Steg
    Lawrence A. Leiter
    Deepak L. Bhatt
    Cardiovascular Drugs and Therapy, 2022, 36 : 1259 - 1259
  • [5] The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus (Nov, 10.1007/s10557-021-07291-y, 2021)
    Pitt, Bertram
    Steg, Gabriel
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (06) : 1259 - 1259
  • [6] Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care
    Danne, Thomas
    Biester, Torben
    Kordonouri, Olga
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : 69 - 77
  • [7] Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?
    Pitt, Bertram
    Bhatt, Deepak L.
    CIRCULATION, 2021, 144 (01) : 4 - 6
  • [8] Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus
    Cui, Haigang
    Luo, Xin
    Chen, Mingwei
    Lu, Jun
    Liu, Johnson J. J.
    CURRENT DRUG TARGETS, 2023, 24 (08) : 648 - 661
  • [9] SGLT1 does compensate for SGLT2 inhibition
    Javier Martinez-Martin, Francisco
    Jimenez-Martin, Natalia
    Sablon-Gonzalez, Nery
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2016, 2 (04) : 256 - 256
  • [10] SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
    Mukhopadhyay, Pradip
    Sanyal, Debmalya
    Chatterjee, Purushottam
    Pandit, Kaushik
    Ghosh, Sujoy
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (08): : 2134 - 2140
12345